Center for Substance Abuse Prevention; Notice of Meeting, 7483-7484 [2010-3227]
Download as PDF
7483
Federal Register / Vol. 75, No. 33 / Friday, February 19, 2010 / Notices
per hour for family and patient
respondents, and $75 per hour for
physicians. There are no Capital Costs
to report. There are no Operating or
Maintenance Costs to report.
ESTIMATE OF ANNUAL HOUR BURDEN
[2010–2013]
Number of
respondents
Type of response
Frequency of
response
Average time
per response
Annual hour
burden
Participant Follow-up .......................................................................................
Physician or Coroner (for CHD) 1 ....................................................................
Physician (for heart failure) 1 ...........................................................................
Participant’s next-of-kin 1 .................................................................................
10,735
491
190
575
1.0
1.0
1.0
1.0
0.2500
0.1667
0.0833
0.1667
2,683.8
81.8
15.8
95.9
Total ..........................................................................................................
11,992
1.0
0.2399
2,877.4
1 Annual
pwalker on DSK8KYBLC1PROD with NOTICES
burden is placed on doctors, hospitals, nursing homes, and respondent relatives/informants through requests for information which will
help in the compilation of the number and nature of new fatal and nonfatal events.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact: Dr.
Hanyu Ni, NIH, NHLBI, 6701 Rockledge
Drive, MSC 7934, Bethesda, MD 20892–
7934, or call non-toll-free number (301)
435–0448 or E-mail your request,
including your address to:
nihanyu@nhlbi.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
VerDate Nov<24>2008
18:05 Feb 18, 2010
Jkt 220001
Dated: January 29, 2010.
Suzanne Freeman,
NHLBI Project Clearance Liaison, National
Institutes of Health.
Michael Lauer,
Director, DCVS, National Institutes of Health.
[FR Doc. 2010–3204 Filed 2–18–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel,
February 11, 2010, 1 p.m. to February
11, 2010, 5 p.m., National Institutes of
Health, Bethesda, MD, 20892 which was
published in the Federal Register on
January 20, 2010, 75 FR 3241–3242.
The meeting will be held March 4,
2010. The meeting time and location
remain the same. The meeting is closed
to the public.
ACTION: Notice of meeting; meeting time
correction.
SUMMARY: A notice was published in the
Federal Register on January 29, 2010,
Volume 75, Number 19, Pages 4830–
4831, announcing a meeting of the
Advisory Committee to the Director on
February 18, 2010. The time published
for the aforementioned meeting is
incorrect and has been changed to 1
p.m.–5 p.m.
DATES: The time of the February 18,
2010, meeting published at 75 FR 4830,
January 29, 2010, is 1 p.m.–5 p.m.
FOR FURTHER INFORMATION CONTACT:
Drue Barrett, PhD, Designated Federal
Officer, ACD, CDC–ES, 1600 Clifton
Road, NE., M/S D–50, Atlanta, Georgia
30333. Telephone: (404) 639–4690. Email: dbarrett@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
[FR Doc. 2010–3199 Filed 2–18–10; 8:45 am]
Dated: February 16, 2010.
Andre Tyler,
Acting Director, Management Analysis and
Services Office,Centers for Disease Control
and Prevention.
BILLING CODE 4140–01–P
[FR Doc. 2010–3324 Filed 2–17–10; 11:15 am]
Dated: February 3, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee to the Director
(ACD), Centers for Disease Control
(CDC) and Prevention—Ethics
Subcommittee (ES); Correction
Centers for Disease Control and
Prevention (CDC), HHS.
AGENCY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Center for Substance Abuse
Prevention; Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
E:\FR\FM\19FEN1.SGM
19FEN1
7484
Federal Register / Vol. 75, No. 33 / Friday, February 19, 2010 / Notices
pwalker on DSK8KYBLC1PROD with NOTICES
Services Administration’s (SAMHSA)
Drug Testing Advisory Board (DTAB)
will meet on March 8, 2010.
The meeting is open to the public and will
include discussion of the Mandatory
Guidelines for Federal Workplace Drug
Testing Programs, including implementation
of the revised Mandatory Guidelines; Federal
drug testing updates from the Department of
Transportation (DOT), the Department of
Defense, and the Nuclear Regulatory
Commission; review of significant changes in
the revised Mandatory Guidelines; review of
the National Laboratory Certification Program
planned implementation of the revised
Mandatory Guidelines; an update on the
revised Federal Custody and Control Form; a
review of the special proficiency testing
program for initial and confirmation testing
for new analytes and new cutoffs; an update
on instrumented initial test facilities; an
update on the DTAB working groups; and a
comparison of HHS and DOT urine collection
requirements.
DTAB members and invited presenters will
participate in this meeting through remote
internet connection. On-site attendance by
the public will be limited to space available.
The meeting can also be accessed by the
public via teleconference. To obtain
teleconference call-in numbers and access
codes, to make arrangements to attend onsite, or to request special accommodations for
persons with disabilities, please register at
the SAMHSA Committees’ Web site at
https://nac.samhsa.gov/Registration/
meetingsRegistration.aspx or communicate
with DTAB’s Program Assistant, Ms. Giselle
Hersh (see contact information below).
SAMHSA would like to ensure that
advisory committee meetings proceed in an
orderly fashion, are conducted in a safe and
secure environment, that the right of free
speech is protected, and that the ability of
SAMHSA Advisory Committees to
accomplish their objectives is not disrupted.
Therefore, the following procedures will be
followed at all DTAB meetings:
• Attendees are subject to security
screening, including identification (driver’s
license) review, metal detector screening, and
inspection of briefcases, packages, etc. Each
attendee will be issued a security badge that
must be worn at all times while in the
building.
• Any interested person who wishes to be
assured of the right to make an oral
presentation during the Public Comment
portion of the DTAB meeting must register
with Ms. Hersh before the meeting.
• Those who have not registered before the
meeting will only be invited to speak at the
discretion of the Chair and should submit
their request to the Designated Federal
Official on the day of the meeting.
• Public Comment participants who are
designated to speak may be questioned only
by the Chair or DTAB members.
• Audience members may not present
comments or questions to DTAB members
unless recognized by the Chair.
• Attendees at the meeting are asked to
maintain order and not display behavior that
is disruptive to the meeting (i.e., shouting
from the audience, loud outbursts).
VerDate Nov<24>2008
18:05 Feb 18, 2010
Jkt 220001
• We ask that attendees not approach the
DTAB table area during the meeting without
permission from the Chair or the Designated
Federal Official.
• The DTAB Chair or Designated Federal
Official will note on the record any
disruptive behavior and will ask the person
to cease the behavior or else leave the
meeting room.
Substantive program information, a
summary of the meeting, and a roster of
DTAB members may be obtained as soon as
possible after the meeting, either by accessing
the SAMHSA Committee Web site, https://
www.nac.samhsa.gov/DTAB/meetings.aspx,
or by contacting Ms. Hersh. The transcript for
the meeting will also be available on the
SAMHSA Committee Web site within three
weeks after the meeting.
Committee Name: Substance Abuse and
Mental Health Services Administration, Drug
Testing Advisory Board.
Date/Time/Type: March 8, 2010 from 10
a.m. to 4:45 p.m. EST: Open.
Place: Sugarloaf and Seneca Conference
Rooms, 1 Choke Cherry Road, Rockville,
Maryland 20857.
Contacts:
Ms. Giselle Hersh, Program Assistant,
SAMHSA Drug Testing Advisory Board, 1
Choke Cherry Road, Room 2–1042,
Rockville, Maryland 20857, Telephone:
240–276–2600, Fax: 240–276–2610, E-mail:
Giselle.Hersh@samhsa.hhs.gov.
Donna M. Bush, PhD, Designated Federal
Official, SAMHSA Drug Testing Advisory
Board, 1 Choke Cherry Road, Room 2–
1033, Rockville, Maryland 20857,
Telephone: 240–276–2600, Fax: 240–276–
2610.
Toian Vaughn,
Committee Management Officer, Substance
Abuse and Mental Health Services
Administration.
Name of Committee: National Institute of
General Medical Sciences Initial Review
Group, Minority Programs Review
Subcommittee B.
Date: March 8–9, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Palomar—Washington, DC,
Washington, DC 20037.
Contact Person: Rebecca H. Johnson, PhD,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 3AN18C, Bethesda,
MD 20892, 301–594–2771,
johnsonrh@nigms.nih.gov.
Name of Committee: National Institute of
General Medical Sciences Initial Review
Group, Minority Programs Review
Subcommittee A.
Date: March 8, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard Marriott Chevy Chase,
Chevy Chase, MD 20815.
Contact Person: Mona R. Trempe, PhD,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN12, Bethesda, MD
20892, 301–594–3998,
trempemo@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
BILLING CODE 4162–20–P
Dated: February 4, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2010–3200 Filed 2–18–10; 8:45 am]
[FR Doc. 2010–3227 Filed 2–18–10; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
E:\FR\FM\19FEN1.SGM
19FEN1
Agencies
[Federal Register Volume 75, Number 33 (Friday, February 19, 2010)]
[Notices]
[Pages 7483-7484]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-3227]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Prevention; Notice of Meeting
Pursuant to Public Law 92-463, notice is hereby given that the
Substance Abuse and Mental Health
[[Page 7484]]
Services Administration's (SAMHSA) Drug Testing Advisory Board (DTAB)
will meet on March 8, 2010.
The meeting is open to the public and will include discussion of
the Mandatory Guidelines for Federal Workplace Drug Testing
Programs, including implementation of the revised Mandatory
Guidelines; Federal drug testing updates from the Department of
Transportation (DOT), the Department of Defense, and the Nuclear
Regulatory Commission; review of significant changes in the revised
Mandatory Guidelines; review of the National Laboratory
Certification Program planned implementation of the revised
Mandatory Guidelines; an update on the revised Federal Custody and
Control Form; a review of the special proficiency testing program
for initial and confirmation testing for new analytes and new
cutoffs; an update on instrumented initial test facilities; an
update on the DTAB working groups; and a comparison of HHS and DOT
urine collection requirements.
DTAB members and invited presenters will participate in this
meeting through remote internet connection. On-site attendance by
the public will be limited to space available. The meeting can also
be accessed by the public via teleconference. To obtain
teleconference call-in numbers and access codes, to make
arrangements to attend on-site, or to request special accommodations
for persons with disabilities, please register at the SAMHSA
Committees' Web site at https://nac.samhsa.gov/Registration/meetingsRegistration.aspx or communicate with DTAB's Program
Assistant, Ms. Giselle Hersh (see contact information below).
SAMHSA would like to ensure that advisory committee meetings
proceed in an orderly fashion, are conducted in a safe and secure
environment, that the right of free speech is protected, and that
the ability of SAMHSA Advisory Committees to accomplish their
objectives is not disrupted. Therefore, the following procedures
will be followed at all DTAB meetings:
Attendees are subject to security screening, including
identification (driver's license) review, metal detector screening,
and inspection of briefcases, packages, etc. Each attendee will be
issued a security badge that must be worn at all times while in the
building.
Any interested person who wishes to be assured of the
right to make an oral presentation during the Public Comment portion
of the DTAB meeting must register with Ms. Hersh before the meeting.
Those who have not registered before the meeting will
only be invited to speak at the discretion of the Chair and should
submit their request to the Designated Federal Official on the day
of the meeting.
Public Comment participants who are designated to speak
may be questioned only by the Chair or DTAB members.
Audience members may not present comments or questions
to DTAB members unless recognized by the Chair.
Attendees at the meeting are asked to maintain order
and not display behavior that is disruptive to the meeting (i.e.,
shouting from the audience, loud outbursts).
We ask that attendees not approach the DTAB table area
during the meeting without permission from the Chair or the
Designated Federal Official.
The DTAB Chair or Designated Federal Official will note
on the record any disruptive behavior and will ask the person to
cease the behavior or else leave the meeting room.
Substantive program information, a summary of the meeting, and a
roster of DTAB members may be obtained as soon as possible after the
meeting, either by accessing the SAMHSA Committee Web site, https://www.nac.samhsa.gov/DTAB/meetings.aspx, or by contacting Ms. Hersh.
The transcript for the meeting will also be available on the SAMHSA
Committee Web site within three weeks after the meeting.
Committee Name: Substance Abuse and Mental Health Services
Administration, Drug Testing Advisory Board.
Date/Time/Type: March 8, 2010 from 10 a.m. to 4:45 p.m. EST:
Open.
Place: Sugarloaf and Seneca Conference Rooms, 1 Choke Cherry
Road, Rockville, Maryland 20857.
Contacts:
Ms. Giselle Hersh, Program Assistant, SAMHSA Drug Testing Advisory
Board, 1 Choke Cherry Road, Room 2-1042, Rockville, Maryland 20857,
Telephone: 240-276-2600, Fax: 240-276-2610, E-mail:
Giselle.Hersh@samhsa.hhs.gov.
Donna M. Bush, PhD, Designated Federal Official, SAMHSA Drug Testing
Advisory Board, 1 Choke Cherry Road, Room 2-1033, Rockville,
Maryland 20857, Telephone: 240-276-2600, Fax: 240-276-2610.
Toian Vaughn,
Committee Management Officer, Substance Abuse and Mental Health
Services Administration.
[FR Doc. 2010-3227 Filed 2-18-10; 8:45 am]
BILLING CODE 4162-20-P